Merck Healthcare KGaA, Darmstadt, Germany.
Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
Curr Med Res Opin. 2022 Nov;38(11):1865-1870. doi: 10.1080/03007995.2022.2071059. Epub 2022 May 12.
Lifelong treatment with levothyroxine (LT4) is the mainstay of management for individuals with hypothyroidism. Many hypothyroid patients start LT4 treatment at a low dose (e.g. 25-50 µg), especially the elderly, those with residual thyroid function, those with low body weight, and those with significant (especially cardiac) comorbidities. Almost half of patients on LT4 replacement therapy demonstrate either under- or over-treatment. Many LT4 preparations have relatively large intervals between tablet strengths at the lower end of their dose ranges (providing 25 µg, 50 µg, and 75 µg tablets), which may represent a barrier to achieving the optimum maintenance treatment for some patients. The availability of intermediate tablet strengths of LT4 in the 25-75 µg range may facilitate precise and effective dose titration of LT4 and may also enable convenient maintenance regimens based on a single LT4 tablet daily, to support adherence to therapy.
对于甲状腺功能减退症患者，长期应用左甲状腺素（LT4）治疗是其主要治疗方法。许多甲状腺功能减退症患者起始 LT4 治疗的剂量较低（例如 25-50μg），尤其是老年人、有残余甲状腺功能者、体重较轻者以及有明显（尤其是心脏）合并症者。几乎一半的 LT4 替代治疗患者存在治疗不足或治疗过度的情况。许多 LT4 制剂在其剂量范围的较低端（提供 25μg、50μg 和 75μg 片剂）的片剂强度之间间隔较大，这可能是某些患者无法达到最佳维持治疗的一个障碍。LT4 中 25-75μg 范围内的中间片剂强度的可用性可能有助于 LT4 的精确和有效剂量滴定，并且还可以基于每日一片 LT4 片剂来实现方便的维持方案，以支持对治疗的依从性。
